TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04776512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP Block With Bupivacain
Description: bilateral lumbar ESP block using 0.375% Bupivacain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia
Description: Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil
Study: NCT06298786

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional 6-minute mastication test
Description: All participants will be evaluated in 3 different phases. First, they will respond to the online TMD screener questionnaire. Then, they will be presentally evaluated using the DC/TMD and finally they will undergo the functional 6-minute mastication test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional 6-minute mastication test
Description: All participants will be evaluated in 3 different phases. First, they will respond to the online TMD screener questionnaire. Then, they will be presentally evaluated using the DC/TMD and finally they will undergo the functional 6-minute mastication test.
Study: NCT02633514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2,iv gtt,d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 75mg/m2,iv gtt,d1-3

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 60Gy/30Fx

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: radiotherapy
Description: 60Gy/30Fx
Study: NCT04869826

Intervention type: DEVICE
Intervention: Pulsewave Health Monitor (PAD-2A) Device
Description: This is an observational, comparison study of blood pressure measurements. The objective of this study is to calibrate the blood pressure measurements of the Pulsewave Health Monitor (PAD-2A) device to be within 5±8 mmHg of the average of the dual-observer auscultatory blood pressure measurements via an aneroid sphygmomanometer (reference device), as per the ISO 81060-2: AMD_2020 universal protocol.
Study: NCT06166615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron (a 5-HT3 receptor antagonist) has been developed as an effective treatment for irritable bowel syndrome-diarrhea (IBD-D) and is used to decrease intestinal motility, stiffen stool consistency, and reduce the number of urgency bowel movements. Since one of the goals of treatment for fecal incontinence is the maintenance of stool consistency, this agent is expected to be effective in treating fecal incontinence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: Psyllium was found to be the most effective at improving symptoms of fecal incontinence among several dietary fibers in a randomized, controlled, single-blind study and is currently used as a first-line treatment for fecal incontinence.
Study: NCT04889638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation Intervention
Description: 1. Pharmacotherapy selection, prescription and monitoring of up to two types of cessation pharmacotherapies: Nicotine replacement therapy (gum, lozenge and transdermal patch) and non-nicotine replacement therapy (varenicline).~2. Remote video-conferencing and mobile phone-based, personalized motivational messaging
Study: NCT04793217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving AIDS Care After Trauma +
Description: ImpACT+ integrates skills for HIV treatment adherence and coping with trauma, tailored to the South African context. This includes exploration of values informing care engagement, recognizing the synergistic stress of sexual trauma and HIV, understanding the contribution of stressors to maladaptive coping, and developing adaptive methods for coping as alternatives to avoidance. ImpACT+ will be delivered in private spaces at the primary care clinic and will consist of 6 individual sessions followed by 6 maintenance check-ins. Individual sessions focus on coping, adherence, and care engagement during an early critical period, while maintenance check-ins reinforce positive change and support ongoing implementation of skills. Evidence supports a 6-session format in low-resource settings. Individual sessions will begin within 2 weeks after the baseline survey and be completed by the 4-month assessment. Maintenance check-ins will begin following the 4-month assessment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Problem-Solving Therapy
Description: Participants will receive three weekly individual sessions of adapted PST. The goal of PST is to identify problems that interfere with daily activities and address them through problem-orientation work. We anticipate stressors will include (a) relationship difficulties, including family stress, (b) financial stress and unemployment, (c) general impact of HIV infection, and (d) overall chronic stress. Thus, PST may indirectly address stressors that may impact care engagement, but will not address the intersection of HIV and trauma specifically.
Study: NCT01184157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic screening
Study: NCT06079112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: 1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
Study: NCT05044806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided remote ischemic conditioning
Description: Before conducting RIC, Doppler ultrasound was used to measure the total occlusion pressure (TOP) of brachial artery, which was then determined as the cuff inflation pressure during RIC. The RIC program encompasses four main components of (1) three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2) one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3) three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of RIC with 3 min intervals of reperfusion in between, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional remote ischemic conditioning
Description: The RIC program encompasses four main components of (1)three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2)one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3)three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of upper limb ischemia on the arm that is opposite to the PCI side with 3 min intervals of reperfusion in between delivered by an automated cuff inflation/deflation device, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
Study: NCT06231849

Intervention type: DIAGNOSTIC_TEST
Intervention: stool analysis
Description: stool analysis to determine number of gut microbiota in subjects with opioid use and its effect on its intoxication.
Study: NCT05044806

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
Study: NCT05292352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LFSD
Description: Assessment of child's usual diet to assess sugar intake in relation to the total usual diet.~Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home.~Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1.
Study: NCT05044806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
Study: NCT05147896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Oral Tablet
Description: Semaglutide Oral Tablets will be introduced to the active arm as per protocol for regular therapy introduction.
Study: NCT04907344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study: NCT05463302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active sleepgift blanket
Description: Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Active sleepgift blanket
Description: Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Sleepgift Blanket
Description: Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Sleepgift Blanket
Description: Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.
Study: NCT05732025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrohydraulic shock wave lithotripsy
Description: Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotary atherectomy
Description: Pre-treatment of severe calcified coronary lesions with rotary atherectomy
Study: NCT06042556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IUD self-removal guide
Description: We previously developed an online guide for IUD self-removal through an iterative process including advice from key expert informants, focus groups, interviews, and a pilot clinical study. It includes an online animation, step-by-step guide, troubleshooting tips, and information about pregnancy and contraception.
Study: NCT05896072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Block
Description: Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances
Study: NCT00935675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg once a day
Study: NCT04961190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy with paroxetine or venlafaxine XR
Description: Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy with paroxetine or venlafaxine XR
Description: Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
Study: NCT06722469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WCI
Description: The WCI group will receive automated messages based on the Health Belief Model (HBM) and Protection Motivation Theory (PMT), including personalized risk assessments, educational videos featuring medical professionals and relatable scenarios, and tailored prompts to encourage mammographic screening.
Study: NCT06722118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV
Description: IV-DXM 4mg/ml, injectable solution. Dosage of 0.25 mg/kg (maximum 5 mg per dose), prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 0.9% NaCl solution, prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
Study: NCT06723093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Medicine Housing Initiative
Description: Through the Social Medicine Housing Initiative, patients will receive access to permanent supportive housing and support services based on a social medicine model. The Housing Initiative provides a housing-first approach which offers housing to individuals without prerequisites (e.g., requiring cessation of substance use, adherence to treatment). Housing will be provided through a rent-geared-to-income model, with participants paying up to 30 percent of their income towards rent.~Participants will also be provided with customized social and medical support within and beyond the University Health Network, tailored to their specific needs and preferences. Patient care will be a collaborative effort involving the housing provider, the Social Medicine team, and community agencies.
Study: NCT06722911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 400 mg on Day 1 and 15 of a 28-day cycle (6 cycles) ; Patients will receive Nimotuzumab 600 mg on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG
Description: Patients will receive nab-paclitaxel 125 mg/m\^2 followed by gemcitabine 1,000 mg/m\^2 as one intravenous infusion over 30-40 minutes on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
Study: NCT06724198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium husk
Description: 3.66 gram Psyllium husk twice daily for 8 weeks
Study: NCT06723548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Patients with MG who fulfill the inclusion criteria will receive Telitacicept 240mg weekly as an adjunct to their medication. Upon reaching MMS, significant symptom improvement, or a QMG score reduction of at least 6 points, Telitacicept is reduced to biweekly doses. Pyridostigmine and NSISTs are tapered based on patient response. Following this, Prednisone is tapered, starting with rapid reduction early and slowing later. If a patient on 60mg Prednisone daily achieves treatment goals within 6-8 weeks of Telitacicept initiation, the tapering sequence is 60mg every other day for 4 weeks, then 30mg daily for 2-4 weeks, and so on, until reaching 5mg daily or 10mg every other day. At this point, Telitacicept may be reduced to 160mg biweekly.
Study: NCT06722716

Intervention type: OTHER
Intervention: Swab collection
Description: Nasopharyngeal swab

Intervention type: OTHER
Intervention: Swab collection
Description: Nasopharyngeal swab
Study: NCT06724562

Intervention type: OTHER
Intervention: Anti-IL1 Therapy
Description: Anti-IL1 is a rescue therapy for FOP patients that is hypothesized to reduce flare activity and subsequent ossification in these patients
Study: NCT06724250

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback therapy
Description: Biofeedback therapy involves the use of specialized equipment to provide real-time feedback on pelvic floor muscle activity. Participants are trained to improve muscle coordination and relaxation through guided exercises, targeting the resolution of dyssynergic defecation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A (Botox )
Description: Botulinum toxin is injected into the pelvic floor muscles to reduce muscle overactivity and improve coordination, aiming to relieve symptoms of dyssynergic defecation.
Study: NCT06724796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Y4BI
Description: The yoga classes will follow the Iyengar method, one of the most widely practiced traditional yoga styles, aimed at promoting body alignment and precision in executing poses (asanas) through the use of props such as blankets, straps, cushions, chairs, and blocks, making the poses accessible to all individuals.~The classes will be conducted once a week, in groups, with each session lasting 1 hour. They will be led by a qualified instructor with over 10 years of teaching experience in yoga. The classes will be adapted for beginners who do not practice yoga regularly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVE
Description: The total body classes will take place once a week, with each session lasting one hour. They will be led by a kinesiology specialist in preventive and adapted physical activities.
Study: NCT06723496

Intervention type: BEHAVIORAL
Intervention: Child Behavioral Checklist (CBCL):is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions for both groups.
Description: is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions.

Intervention type: BEHAVIORAL
Intervention: Child Behavioral Checklist (CBCL):is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions for both groups.
Description: is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions.

Intervention type: BEHAVIORAL
Intervention: parent report on child's responses to stress (PCT):is a questionnaire which is used to obtain mothers' and fathers' reports of their children's coping with cancer
Description: It includes a list of 12 cancer -related stressors (e.g., missing school, frequent hospital or clinic visits, changes in personal appearance), and 57 items reflecting voluntary (coping) and involuntary (automatic) stress responses of children /adolescents in response to cancer-related stressors

Intervention type: BEHAVIORAL
Intervention: Symptom Checklist -90- Revised (SCL-90-R) for parents
Description: It is a method to evaluate psychological problems and identify symptoms, it includes 90 symptoms and evaluate nine symptomatic dimensions

Intervention type: BEHAVIORAL
Intervention: Symptom Checklist -90- Revised (SCL-90-R) for parents
Description: It is a method to evaluate psychological problems and identify symptoms, it includes 90 symptoms and evaluate nine symptomatic dimensions

Intervention type: BEHAVIORAL
Intervention: posttraumatic stress disorders by posttraumatic check list -5 (PCL-5) for parents
Description: It is a 20 -item measure that assess the 20 DSM-5 symptoms of PTSD.